Skip to Content

Adhera Therapeutics Inc ATRX

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Adhera Therapeutics Inc is a biopharmaceutical company. It discovers, acquires, develops and commercializes proprietary drug therapeutics for unmet medical needs in the USA, Europe, and international markets. Its therapeutic focus is the disease intersection of hypertension, arthritis, pain, and oncology. It generates revenue from license fees, milestone-related development fees, and royalties by licensing rights to its product candidates. The company has terminated current business and is seeking for opportunities.

4721 Emperor Boulevard, Suite 350
Durham, NC, 27703
T +1 919 578-5901
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Distressed
Employees 2